Celecoxib in Treating Patients With Bladder Cancer

NCT00006124 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

152

Enrollment

NIH

Sponsor class

Conditions

Recurrent Bladder Cancer

Interventions

DRUG: celecoxib
DRUG: placebo

Sponsor

National Cancer Institute (NCI)